Docking Study of Ligands Targeting NLRP3 Inflammatory Pathway for Endodontic Diseases

被引:1
作者
Erdag, Emine [1 ]
Kucuk, Meltem [2 ]
Aksoy, Umut [2 ]
Abacioglu, Nurettin [3 ]
Sehirli, Ahmet Ozer [4 ]
机构
[1] Near East Univ, Fac Pharm, Dept Pharmaceut Chem, Mersin 10, Lefkosa Trnc, Turkiye
[2] Near East Univ, Fac Dent, Dept Endodont, Mersin 10, Lefkosa Trnc, Turkiye
[3] Near East Univ, Fac Pharm, Dept Pharmacol, Mersin 10, Lefkosa Trnc, Turkiye
[4] Near East Univ, Fac Dent, Dept Pharmacol, Mersin 10, Lefkosa Trnc, Turkiye
来源
CHEMICAL METHODOLOGIES | 2023年 / 7卷 / 03期
关键词
NLRP3 inflammasome inhibition; Caspase-1; inhibition; Endodontic diseases; Molecular docking; INHIBITOR;
D O I
10.22034/CHEMM.2023.367137.1623
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The NLRP3 (NOD-like receptor family containing a pyrin domain 3) inflammasome pathway has a crucial role in the dental immune system and is associated with the activation of the dental immune response. Therefore, it is a specific target for drug molecules to be selected in the treatment of endodontic diseases. Various NLRP3 inflammatory and caspase-1 inhibitors that exhibit effective inhibition against inflammatory conditions have been identified in previous studies. In this study, the human NLRP3 model was constructed by the loop modeling method using computer -aided programs. Binding affinities, inhibition constants (Ki), and ligand-protein interactions of the selected ligands were calculated and investigated by molecular docking simulation against the inflammasome NLRP3 and caspase-1. Binding modes and calculations were performed according to Lamarckian genetic algorithm. The calculated docking scores for each ligand used in this study were between the range of-5.1 and-11.8 kcal/mol for the inhibitory activity. CY-09 (a NLRP3 inflammasome inhibitor) and VX-765 (a caspase-1 inhibitor) were shown to have the most desirable binding affinities, Ki values, and strong binding interactions in the NLRP3 and human caspase-1 binding pockets, respectively. The combination of CY-09 and VX-765 ligands can be used to prevent inflammation in the treatment of endodontic diseases. These inhibitors could be used in the future treatment of endodontic infections and to improve the viability of root canal drugs and pulp capping materials.
引用
收藏
页码:200 / 210
页数:11
相关论文
共 35 条
  • [1] Investigation of microbial profile, levels of endotoxin and lipoteichoic acid in teeth with symptomatic irreversible pulpitis: a clinical study
    Arruda-Vasconcelos, R.
    Louzada, L. M.
    Feres, M.
    Tomson, P. L.
    Cooper, P. R.
    Gomes, B. P. F. A.
    [J]. INTERNATIONAL ENDODONTIC JOURNAL, 2021, 54 (01) : 46 - 60
  • [2] Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants
    Bachmann, KA
    Lewis, JD
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (06) : 1064 - 1072
  • [3] IL-1β Favors Osteoclastogenesis Via Supporting Human Periodontal Ligament Fibroblasts
    Bloemen, Veerle
    Schoenmaker, Ton
    de Vries, Teun J.
    Everts, Vincent
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112 (07) : 1890 - 1897
  • [4] Bacteria and virulence factors in periapical lesions associated with teeth following primary and secondary root canal treatment
    Bronzato, J. D.
    Davidian, M. E. S.
    de Castro, M.
    De-Jesus-Soares, A.
    Ferraz, C. C. R.
    Almeida, J. F. A.
    Marciano, M. A.
    Gomes, B. P. F. A.
    [J]. INTERNATIONAL ENDODONTIC JOURNAL, 2021, 54 (05) : 660 - 671
  • [5] Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review
    Cheng, Ran
    Wu, Zhiwu
    Li, Mingming
    Shao, Meiying
    Hu, Tao
    [J]. INTERNATIONAL JOURNAL OF ORAL SCIENCE, 2020, 12 (01)
  • [6] The extent of pyroptosis varies in different stages of apical periodontitis
    Cheng, Ran
    Feng, Yuchao
    Zhang, Rui
    Liu, Wen
    Lei, Lei
    Hu, Tao
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (01): : 226 - 237
  • [7] FMDV Leader Protein Interacts with the NACHT and LRR Domains of NLRP3 to Promote IL-1β Production
    Choudhury, Sk Mohiuddin
    Ma, Xusheng
    Li, Yuanyuan
    Nian, Xiaofeng
    Luo, Zhikuan
    Ma, Yonghua
    Zhu, Zixiang
    Yang, Fan
    Cao, Weijun
    Zheng, Haixue
    [J]. VIRUSES-BASEL, 2022, 14 (01):
  • [8] A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
    Coll, Rebecca C.
    Robertson, Avril A. B.
    Chae, Jae Jin
    Higgins, Sarah C.
    Munoz-Planillo, Raul
    Inserra, Marco C.
    Vetter, Irina
    Dungan, Lara S.
    Monks, Brian G.
    Stutz, Andrea
    Croker, Daniel E.
    Butler, Mark S.
    Haneklaus, Moritz
    Sutton, Caroline E.
    Nunez, Gabriel
    Latz, Eicke
    Kastner, Daniel L.
    Mills, Kingston H. G.
    Masters, Seth L.
    Schroder, Kate
    Cooper, Matthew A.
    O'Neill, Luke A. J.
    [J]. NATURE MEDICINE, 2015, 21 (03) : 248 - +
  • [9] Inhibiting the NLRP3 Inflammasome
    El-Sharkawy, Lina Y.
    Brough, David
    Freeman, Sally
    [J]. MOLECULES, 2020, 25 (23):
  • [10] Tranilast directly targets NLRP3 to treat inflammasome-driven diseases
    Huang, Yi
    Jiang, Hua
    Chen, Yun
    Wang, Xiaqiong
    Yang, Yanqing
    Tao, Jinhui
    Deng, Xianming
    Liang, Gaolin
    Zhang, Huafeng
    Jiang, Wei
    Zhou, Rongbin
    [J]. EMBO MOLECULAR MEDICINE, 2018, 10 (04)